MIT and Affiliates invest Rs 198 Cr in Medi Assist Healthcare Services

IMT News Desk
IMT News Desk
· 2 min read
Coin on wooden table in front of green bokeh background. coins a concept of investment and saving moneys.

The company further solidifies its commitment to maintaining a robust capital structure, thereby fueling innovation-led growth

Medi Assist Healthcare Services announced an investment from Massachusetts Institute of Technology (MIT) and 238 Plan Associates (an affiliate of MIT). The aggregate investment of Rs 198 crores was secured through a preferential allotment on a private placement basis.

Under the preferential allotment, Medi Assist has issued 37,01,000 fully paid-up equity shares with a face value of Rs 5 each, at an issue price of Rs 535 per share, for a total consideration of Rs 198 crores. The issue of shares under preferential allotment received unanimous approval from the Board of Medi Assist at their meeting held on August 7, 2025, and was strongly supported by shareholders in an Extra-ordinary General Meeting (EGM) held on September 4, 2025, with an overwhelming 99.15 per cent of votes cast in favor of the transaction.

This capital infusion closely follows the acquisition of Fairfax-owned Paramount Health Services & Insurance TPA Private Limited in July 2025 by Medi Assist Insurance TPA, a wholly owned subsidiary of Medi Assist and Medi Assist’s strategic collaboration for technology solutions in June 2025 with Star Health Insurance and Allied Services, India’s leading private and retail segment health insurer. With this successful capital raise, the company further solidifies its commitment to maintaining a robust capital structure, thereby fueling innovation-led growth.

Satish V N Gidugu, Chief Executive Officer, Medi Assist, stated, “This investment from MIT unequivocally reaffirms Medi Assist’s mission to spearhead India’s digital health transformation. Technology remains at the core of our operations, enabling us to make healthcare simpler, faster, and more transparent. We are steadfast in our commitment to accelerate innovation in AI-led health benefit solutions that improve member experience and payer outcomes, elevating healthcare access to an unprecedented level for millions of people.”

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk